Internal Medicine

Breast Cancer   

Questions discussed in this category



Would you continue KEYNOTE-522 neoadjuvant therapy? The patient has a PMH of sarcoidosis with no stroke risk factors. No residual deficits. 

Since both pregnancy and cancer are risk factors for VTE, is there data to guide when or if we should prophylactically anticoagulate? If so, what shou...

Can patients be re-challenged after developing ILD? Is the toxicity seen with T-Dxd a potential barrier to use?  Do you feel the dosing used in...

In a patient with Stage IE DLBCL, is your treatment volume postchemo ISRT or whole breast? Would you consolidate if a lumpectomy was performed prior t...


Papers discussed in this category


Lancet (London, England), 2014-03-22

The New England journal of medicine, 2011-06-23

Journal of the National Cancer Institute, 2005-09-07

The New England journal of medicine, 2016-07-21

Journal of the National Cancer Institute, 2010-07-07

J Natl Cancer Inst, 2006 Jul 5

J. Natl. Cancer Inst., 2010-07-07

J. Clin. Oncol., 2003-10-01

J Natl Cancer Inst, 2011 Jul 09

Br J Clin Pharmacol, 2020 Jun 02

J. Clin. Oncol., 2004-04-15

Int J Radiat Oncol Biol Phys,

PloS one, 2017

Circulation, 2016-03-29

N. Engl. J. Med.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991 Feb

Journal of stroke, 2020 Jan 31